BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones LK, Tilberry S, Gregor C, Yaeger LH, Hu Y, Sturm AC, Seaton TL, Waltz TJ, Rahm AK, Goldberg A, Brownson RC, Gidding SS, Williams MS, Gionfriddo MR. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. Implement Sci 2021;16:40. [PMID: 33849601 DOI: 10.1186/s13012-021-01108-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Geest SD, Thys A, Zullig LL. Implementation science: accelerating the pharma pipeline to its full potential. Journal of Comparative Effectiveness Research 2022. [DOI: 10.2217/cer-2022-0152] [Reference Citation Analysis]
2 Mchugh SM, Riordan F, Curran GM, Lewis CC, Wolfenden L, Presseau J, Lengnick-hall R, Powell BJ. Conceptual tensions and practical trade-offs in tailoring implementation interventions. Front Health Serv 2022;2. [DOI: 10.3389/frhs.2022.974095] [Reference Citation Analysis]
3 Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol 2022. [PMID: 36267039 DOI: 10.1002/clc.23935] [Reference Citation Analysis]
4 Tewari P, Sweeney BF, Lemos JL, Shapiro L, Gardner MJ, Morris AM, Baker LC, Harris AS, Kamal RN. Evaluation of Systemwide Improvement Programs to Optimize Time to Surgery for Patients With Hip Fractures: A Systematic Review. JAMA Netw Open 2022;5:e2231911. [DOI: 10.1001/jamanetworkopen.2022.31911] [Reference Citation Analysis]
5 Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, Jacobson TA, Duell PB. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol 2022:S1933-2874(22)00245-8. [PMID: 36115813 DOI: 10.1016/j.jacl.2022.09.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Sjölander A, Carrero JJ. Intensity of and Adherence to Lipid‐Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. JAHA. [DOI: 10.1161/jaha.122.025813] [Reference Citation Analysis]
7 Jones LK, Sturm AC, Gionfriddo MR. Translating guidelines into practice via implementation science: an update in lipidology. Curr Opin Lipidol 2022. [PMID: 35779062 DOI: 10.1097/MOL.0000000000000835] [Reference Citation Analysis]
8 Martsevich SY, Lukina YV, Kutishenko NP, Zagrebelnyy AV, Tolpygina SN, Voronina VP, Dmitrieva NA, Lerman OV, Nekoshnova ES, Budaeva IV, Blagodatskikh SV, Aslanova BB. Challenges of Statin Therapy in Clinical Practice (According to Outpatient Register «PROFILE» Data). Racionalʹnaâ farmakoterapiâ v kardiologii 2022;18:73-8. [DOI: 10.20996/1819-6446-2022-02-02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Barbieri JS, Beidas RS, Gondo GC, Fishman J, Williams NJ, Armstrong AW, Ogdie AR, Mehta N, Gelfand JM. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatol 2022. [PMID: 35044419 DOI: 10.1001/jamadermatol.2021.4467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Talic S, Marquina C, Zomer E, Asenso RO, Petrova M, Vargas-Torres S, Abushana D, Wolfe R, Lybrand S, Thomson D, Stratton G, Liew D, Ademi Z. Attainment of low-density lipoprotein cholesterol goals in statin treated patients: real-world evidence from Australia. Curr Probl Cardiol 2021;:101068. [PMID: 34818528 DOI: 10.1016/j.cpcardiol.2021.101068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, Hacke W, Ringleb PA; SPACE-2 study group. Successful implementation of best medical treatment for patients with asymptomatic carotid artery stenosis within a randomized controlled trial (SPACE-2). Neurol Res Pract 2021;3:62. [PMID: 34666833 DOI: 10.1186/s42466-021-00153-w] [Reference Citation Analysis]
12 López B, Torrent‐fontbona F, Masana Marín L, Zamora A. HTE 3.0: Knowledge‐based systems in cascade for familial hypercholesterolemia detection and dyslipidemia treatment. Expert Systems 2022;39. [DOI: 10.1111/exsy.12835] [Reference Citation Analysis]
13 Jones LK, Walters N, Brangan A, Ahmed CD, Gatusky M, Campbell-Salome G, Ladd IG, Sheldon A, Gidding SS, McGowan MP, Rahm AK, Sturm AC. Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study. J Pers Med 2021;11:587. [PMID: 34205662 DOI: 10.3390/jpm11060587] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]